EGFR and adenocarcinoma: Especially, it is interesting that in the subgroup with adenocarcinoma and EGFR mutation, patients with sFRP5 methylation have a significantly shorter PFS than those without sFRP5 methylation, While in nonsmokers without EGFR mutation, patients without sFRP1 methylation have a longer PFS compared with patients with its methylation(9.7 ms vs 2.0 ms, p = 0.05).